Deep Track Capital, LP
- SEC CIK
- 0001856083
- Latest filing
- Aug 14, 2026
Holdings in Q4 2023
Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.
- Positions
- 57
- −5 vs. Q3 2023
- Portfolio value
- $2.85B
- +$275.8M (+10.7%) vs. Q3 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| INSMINSMED Inc | COM PAR $.01 | 5,350,000 | $165.8M | 5.8% | −650,000−10.8% | Reduced | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 4,063,676 | $148.3M | 5.2% | +517,241+14.6% | Added | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 2,000,000 | $143.2M | 5.0% | −600,000−23.1% | Reduced | History |
| GHGuardant Health, Inc. | COM | 5,000,000 | $135.3M | 4.7% | +950,000+23.5% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 300,000 | $114.1M | 4.0% | +300,000 | New | History |
| ALKSAlkermes plc. | SHS | 4,000,000 | $111.0M | 3.9% | +200,000+5.3% | Added | History |
| PLRXPliant Therapeutics, Inc. | COM | 5,750,000 | $104.1M | 3.6% | +250,000+4.5% | Added | History |
| DVAXDynavax Technologies Corp | COM NEW | 7,093,214 | $99.2M | 3.5% | +336,258+5.0% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 1,000,000 | $79.6M | 2.8% | −140,745−12.3% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,631,728 | $79.1M | 2.8% | +668,461+22.6% | Added | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 11,869,297 | $76.4M | 2.7% | −3,130,703−20.9% | Reduced | History |
| PACBPacific Biosciences of California, Inc. | COM | 7,000,000 | $68.7M | 2.4% | +1,000,000+16.7% | Added | History |
| NTLAIntellia Therapeutics, Inc. | COM | 2,250,000 | $68.6M | 2.4% | +250,000+12.5% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 7,370,000 | $66.3M | 2.3% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 2,323,456 | $64.9M | 2.3% | −90,917−3.8% | Reduced | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 3,187,415 | $63.4M | 2.2% | 00.0% | Unchanged | History |
| IONSIonis Pharmaceuticals Inc | COM | 1,249,068 | $63.2M | 2.2% | −1,585,001−55.9% | Reduced | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 3,490,506 | $63.1M | 2.2% | 00.0% | Unchanged | History |
| GERNGeron Corp | COM | 29,583,449 | $62.4M | 2.2% | +3,883,449+15.1% | Added | History |
| EDITEditas Medicine, Inc. | COM | 5,473,086 | $55.4M | 1.9% | −1,628,849−22.9% | Reduced | History |
| AMAMAmbrx Biopharma, Inc. | COM | 3,710,412 | $52.8M | 1.9% | +3,710,412 | New | History |
| SRPTSarepta Therapeutics, Inc. | COM | 500,000 | $48.2M | 1.7% | +500,000 | New | History |
| TRMLTourmaline Bio, Inc. | COM | 1,815,854 | $47.5M | 1.7% | +1,815,854 | New | History |
| HLVXHilleVax, Inc. | COM | 2,900,000 | $46.5M | 1.6% | 00.0% | Unchanged | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 2,284,372 | $46.3M | 1.6% | −493,735−17.8% | Reduced | History |
| ABVXAbivax S.A. | SPONSORED ADS | 4,297,438 | $46.0M | 1.6% | +4,297,438 | New | History |
| RAPTRAPT Therapeutics, Inc. | COM | 1,793,966 | $44.6M | 1.6% | +293,966+19.6% | Added | History |
| ANABAnaptysbio, Inc | COM | 2,036,990 | $43.6M | 1.5% | +691,177+51.4% | Added | History |
| IMVTImmunovant, Inc. | COM | 1,000,000 | $42.1M | 1.5% | −1,797,955−64.3% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,952,760 | $42.0M | 1.5% | +1,952,760 | New | History |
| OCULOcular Therapeutix, Inc | COM | 9,230,769 | $41.2M | 1.4% | +9,230,769 | New | History |
| ACLXArcellx, Inc. | COMMON STOCK | 725,145 | $40.2M | 1.4% | +725,145 | New | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 6,100,000 | $39.6M | 1.4% | +100,000+1.7% | Added | History |
| SLNSilence Therapeutics plc | ADS | 1,951,580 | $33.9M | 1.2% | 00.0% | Unchanged | History |
| ORTXOrchard Therapeutics plc | SPON ADS NEW | 2,041,670 | $33.6M | 1.2% | 00.0% | Unchanged | History |
| NUVLNuvalent, Inc. | COM | 450,000 | $33.1M | 1.2% | +450,000 | New | History |
| ANIPAni Pharmaceuticals Inc | COM | 600,000 | $33.1M | 1.2% | +200,000+50.0% | Added | History |
| NRIXNurix Therapeutics, Inc. | COM | 2,997,830 | $30.9M | 1.1% | 00.0% | Unchanged | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 2,537,176 | $27.8M | 1.0% | −212,824−7.7% | Reduced | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 1,930,894 | $27.1M | 0.9% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 2,000,000 | $26.6M | 0.9% | −403,672−16.8% | Reduced | History |
| AGENAgenus Inc | COM NEW | 31,697,539 | $26.2M | 0.9% | 00.0% | Unchanged | History |
| CYTKCytokinetics Inc | COM NEW | 288,949 | $24.1M | 0.8% | +288,949 | New | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 1,062,881 | $23.7M | 0.8% | +640,634+151.7% | Added | History |
| RPTXRepare Therapeutics Inc. | COM | 2,992,731 | $21.8M | 0.8% | −75,000−2.4% | Reduced | History |
| SRRKScholar Rock Holding Corp | COM | 1,011,829 | $19.0M | 0.7% | +657,974+185.9% | Added | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 300,000 | $12.2M | 0.4% | −1,615,000−84.3% | Reduced | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 2,523,000 | $11.8M | 0.4% | 00.0% | Unchanged | History |
| NKTRNektar Therapeutics | COM | 18,400,000 | $10.4M | 0.4% | 00.0% | Unchanged | History |
| RLMDRelmada Therapeutics, Inc. | COM | 2,044,507 | $8.46M | 0.3% | −793,311−28.0% | Reduced | History |
| ALLKAllakos Inc. | COM | 2,510,736 | $6.85M | 0.2% | +2,510,736 | New | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 828,485 | $6.45M | 0.2% | 00.0% | Unchanged | History |
| PTGXProtagonist Therapeutics, Inc | COM | 275,201 | $6.31M | 0.2% | +275,201 | New | History |
| JAZZJazz Pharmaceuticals plc | SHS USD | 48,280 | $5.94M | 0.2% | −1,089,765−95.8% | Reduced | History |
| VIGLVigil Neuroscience, Inc. | COM | 1,594,931 | $5.39M | 0.2% | −172,200−9.7% | Reduced | History |
| ALGSAligos Therapeutics, Inc. | COM | 6,102,770 | $4.05M | 0.1% | +6,102,770 | New | History |
| GHRSGH Research PLC | ORDINARY SHARES | 499,400 | $2.90M | 0.1% | 00.0% | Unchanged | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q3 2023 (18)
Positions held at the end of Q3 2023 that are gone from this filing.
| Security | Class | Shares in Q3 2023 | Value in Q3 2023 | % of portfolio in Q3 2023 | History |
|---|---|---|---|---|---|
| NVCRNovoCure Ltd | ORD SHS | 2,500,000 | $40.4M | 1.6% | History |
| NBIXNeurocrine Biosciences Inc | Stock | 300,000 | $33.8M | 1.3% | History |
| BEAMBeam Therapeutics Inc. | COM | 1,015,641 | $24.4M | 0.9% | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 1,259,335 | $23.1M | 0.9% | History |
| BNTXBioNTech SE | SPONSORED ADS | 200,000 | $21.7M | 0.8% | History |
| MRNAModerna, Inc. | Stock | 200,000 | $20.7M | 0.8% | History |
| PNTPOINT Biopharma Global Inc. | COM | 2,781,565 | $18.6M | 0.7% | History |
| MORFMorphic Holding, Inc. | COM | 470,647 | $10.8M | 0.4% | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 2,513,044 | $10.4M | 0.4% | History |
| NUVBNuvation Bio Inc. | COM CL A | 7,720,688 | $10.3M | 0.4% | History |
| ATXSAstria Therapeutics, Inc. | COM | 1,037,873 | $7.74M | 0.3% | History |
| TXG10x Genomics, Inc. | CL A COM | 182,691 | $7.54M | 0.3% | History |
| NVAXNovavax Inc | COM NEW | 1,000,000 | $7.24M | 0.3% | History |
| SLRNACELYRIN, Inc. | COM | 551,289 | $5.61M | 0.2% | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 328,424 | $2.43M | 0.1% | History |
| HRTXHeron Therapeutics, Inc. | COM | 2,086,704 | $2.15M | 0.1% | History |
| ETNB89bio, Inc. | COM | 91,078 | $1.41M | 0.1% | History |
| IPSCCentury Therapeutics, Inc. | COM | 543,008 | $1.09M | <0.1% | History |